Vitamin D2026-09

Correcting Vitamin D Deficiency to Prevent Paclitaxel-Induced Peripheral Neuropathy: A Practice Change Evaluation.

Singh Ranju Jha, Schneider Susan M, Thompson Julie A, Khan Abir et al. — Clinical journal of oncology nursing

Summary

A recent study explored whether correcting vitamin D deficiency could help reduce nerve damage, known as peripheral neuropathy, in breast cancer patients undergoing paclitaxel chemotherapy. The findings suggest that recommending vitamin D supplementation might lower the incidence of this common side effect. This offers a potential way to improve quality of life for patients receiving certain cancer treatments.

AI-generated summary — read the original

Key points

Chemotherapy drugs like paclitaxel can cause nerve damage, a common side effect known as peripheral neuropathy.
This study found a link between low vitamin D levels and a higher risk of developing this nerve damage.
Recommending vitamin D supplementation appeared to reduce the occurrence of nerve damage in breast cancer patients receiving paclitaxel.
Notably, all patients in the study who had insufficient vitamin D levels experienced peripheral neuropathy.

What the study looked at

What question did this study ask? This study investigated whether recommending vitamin D supplementation could help reduce a common side effect of certain chemotherapy drugs: peripheral neuropathy, which is nerve damage causing pain, numbness, or tingling. Specifically, it looked at breast cancer patients receiving paclitaxel, a chemotherapy agent known to cause this issue, and whether addressing vitamin D deficiency could make a difference. How was the study conducted? Researchers at a rural community cancer center conducted a "quality improvement project." They compared two groups of breast cancer patients undergoing paclitaxel treatment. The first group received standard care, while the second group, treated after a change in practice, was recommended vitamin D supplementation. They then tracked the incidence of peripheral neuropathy in both groups to see if the recommendation had an effect. What did the study find? The study observed a reduction in the incidence of peripheral neuropathy after the vitamin D supplementation recommendation was implemented. Before the change, 80% of patients experienced nerve damage, which decreased to 67% after the recommendation. Notably, all patients in the study who had insufficient vitamin D levels developed peripheral neuropathy, suggesting a strong link between vitamin D status and this side effect.

Dietary takeaway

While this study suggests a potential benefit of vitamin D supplementation for chemotherapy-induced nerve damage, it's important to remember that this is one evaluation and not a definitive clinical trial. For general health, ensuring adequate vitamin D intake through foods like fatty fish (salmon, mackerel), fortified dairy products, and some mushrooms, or through sun exposure, is always beneficial. Patients undergoing chemotherapy should discuss any vitamin D supplementation with their healthcare team to ensure it's appropriate for their specific treatment plan.

Abstract

BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a persistent problem in ambulatory oncology and is associated with low serum vitamin D levels. OBJECTIVES: This quality improvement project evaluated a practice change at a rural community cancer center (preimplementation: N = 20; postimplementation: N = 27) aimed at mitigating CIPN associated with paclitaxel treatment in patients with breast cancer by recommending vitamin D supplementation. The key goal was to reduce CIPN incidence by at least 10%. METHODS: A pre-/postimplementation comparison of CIPN incidence among patients with breast cancer receiving paclitaxel was used before (January 2022 to December 2023) and after (June 2024 to December 2024) a practice change recommending vitamin D supplementation. FINDINGS: CIPN incidence decreased from 80% (n = 16 of 20) preimplementation to 67% (n = 18 of 27) postimplementation, a 13% reduction that met the 10% goal. All patients with vitamin D insufficiency (N = 11) developed CIPN.

View on PubMed →DOI: 10.1188/26.CJON.375-379